Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants

BMJ Open

Volumn 2, Issue 2, 2012, Pages

  Castro, Victor M ^a   Gallagher, Patience J ^b   Clements, Caitlin C ^b   Murphy, Shawn N ^b   Gainer, Vivian S ^a   Fava, Maurizio ^b   Weilburg, Jeffrey B ^b   Churchill, Susanne E ^a   Kohane, Isaac S ^c   Iosifescu, Dan V ^d   Smoller, Jordan W ^b   Perlis, Roy H ^b  

^a PARTNERS HEALTHCARE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INCIDENT USER COHORT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; UNITED KINGDOM;

EID: 84860902913     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000544     Document Type: Article

References (53)

1. U.S. Sales and Prescription Information. IMS Health, 2009. (accessed 15 Mar 2012).
2. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: American Psychiatric Association (APA), 2010.
3. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
5. Ramage AG, Villalon CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008;29:472-81.
6. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9. (Pubitemid 34848222)
7. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003;5:517-21. (Pubitemid 37021646)
8. Serebruany VL, O'Connor CM, Krishnan RR, et al. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther 2005;10:163-4. (Pubitemid 41376973)
9. Ungvari Z, Pacher P, Koller A. Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol 2000;35:849-54. (Pubitemid 30327512)
10. van Melle JP, Buikema H, van den Berg MP, et al. Sertraline causes strong coronary vasodilation: possible relevance for cardioprotection by selective serotonin reuptake inhibitors. Cardiovasc Drugs Ther 2004;18:441-7. (Pubitemid 40487022)
11. Singhal AB, Topcuoglu MA, Dorer DJ, et al. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology 2005;64:1008-13. (Pubitemid 40388453)
12. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 2006;98:42-7. (Pubitemid 43902679)
13. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-8. (Pubitemid 32897004)
14. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82.
15. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006;20:143-51. (Pubitemid 43261698)
16. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81. (Pubitemid 351822152)
17. Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008;168:180-5. (Pubitemid 351185885)
18. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163:59-64. (Pubitemid 36091601)
19. Wallerstedt SM, Gleerup H, Sundstrom A, et al. Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009;18:412-16.
20. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women's health initiative study. Arch Intern Med 2009;169:2128-39.
21. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004;65:1642-53.
22. Trifiro G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol 2010;30:252-8.
23. Wu CS, Wang SC, Cheng YC, et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011;168:511-21.
24. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
25. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002;33:1465-73. (Pubitemid 34619941)
26. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf 2009;18:196-202.
27. Surtees PG, Wainwright NW, Luben RN, et al. Psychological distress, major depressive disorder, and risk of stroke. Neurology 2008;70:788-94.
28. Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham study. Stroke 2007;38:16-21. (Pubitemid 46035600)
29. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006;119:719-27. (Pubitemid 44291626)
30. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the nurses' health study. J Am Coll Cardiol 2009;53:950-8.
31. Murphy SN, Mendis M, Hackett K, et al. Architecture of the opensource clinical research chart from informatics for integrating biology and the bedside. AMIA Annu Symp Proc 2007:548-52.
32. Murphy S, Churchill S, Bry L, et al. Instrumenting the health care enterprise for discovery research in the genomic era. Genome Res 2009;19:1675-81.
33. Murphy SN, Weber G, Mendis M, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc 2010;17:124-30.
34. Vidal X, Ibanez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008;31:159-68. (Pubitemid 351158526)
35. Apparsundaram S, Stockdale DJ, Henningsen RA, et al. Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. J Pharmacol Exp Ther 2008;327:982-90.
36. Martin RS, Henningsen RA, Suen A, et al. Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors. J Pharmacol Exp Ther 2008;327:991-1000.
37. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2. (Pubitemid 38117171)
38. Storustovu S, Sanchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004;142:172-80. (Pubitemid 38698206)
39. Klein N, Sacher J, Geiss-Granadia T, et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007;191:333-9. (Pubitemid 46354624)
40. Zhong H, Haddjeri N, Sanchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter-a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 2012;219:1-13.
41. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9 (Suppl 1):19-26. (Pubitemid 24107713)
42. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22. (Pubitemid 28016506)
43. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007;151:737-48. (Pubitemid 47075311)
44. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58. (Pubitemid 28022649)
45. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-68.
46. Bennett S. Analysis of survival data by the proportional odds model. Stat Med 1983;2:273-7. (Pubitemid 13020140)
47. Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010;33:526-31.
48. Brownstein JS, Freifeld CC. HealthMap: the development of automated real-time internet surveillance for epidemic intelligence. Euro Surveill 2007;12:E071129-25.
49. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of depressive symptomatology, clinician rating (IDS-C) and Self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004;34:73-82. (Pubitemid 38139442)
50. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007;38:3049-51. (Pubitemid 350035702)
51. Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005;25:561-4. (Pubitemid 41669050)
52. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004;91:119-28. (Pubitemid 38120206)
53. Matchar DB, Thakur ME, Gross I, et al. Testing for cytochrome p450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep) 2007;146:1-77.